Clinical Trials

Inclusion Criteria

• Must meet the International Headache Society criteria for chronic migraine (International Classification of Headache Disorders, 3rd edition, Headache Classification Committee of the International Headache Society, 2013)
• Subjects must be between the ages of 18 and 80 years old.
• Must be stable on current migraine treatment regimen
  • Stability is defined as no major changes in therapy contemplated within the next 4 months

Exclusion Criteria

• Other light sensitive conditions, such as iritis and blepharospasm
• Best-corrected visual acuity less than 20/40 
• Diseases of the retina, such as diabetic retinopathy and macular degeneration.
• Use of medications known to affect the eye (e.g. chloroquine, hydroxychloroquine, ethambutol, amiodarone)
• Due to constraints on the manufacture and mounting of study lenses into frames, the study must exclude anyone very nearsighted (more than 4 diopters),  very farsighted (more than 2 diopters), has more than 2.5 diopters of astigmatism
• Must not have had any botulinum toxin injections or other nerve block treatments within 4 months of enrollment, and can not receive any further blocks until the study is completed because of the cyclical effects on patients undergoing these treatments
• Continuous daily headache (a headache frequency of 100%) or do not have a headache frequency of at least 50%
• Has medication overuse headaches 
  • A history of medication overuse who has not overused abortive medications for the past 4 months can be included
• Abuses alcohol or uses illicit drugs
• Considered to be from vulnerable populations, including pregnant women, prisoners, mentally disabled, has cognitive or decisional impairment, or is a ward of the state